Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/158647
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSotorra-Figuerola, Dídac-
dc.contributor.authorSánchez Torres, Alba-
dc.contributor.authorValmaseda Castellón, Eduardo-
dc.contributor.authorGay Escoda, Cosme-
dc.date.accessioned2020-05-05T11:10:16Z-
dc.date.available2020-05-05T11:10:16Z-
dc.date.issued2016-04-01-
dc.identifier.issn1989-5488-
dc.identifier.urihttp://hdl.handle.net/2445/158647-
dc.description.abstractBackground: to determine the clinical characteristics of Continuous Neuropathic Orofacial Pain in patients that suffer Persistent Idiopathic Facial Pain (PIFP), Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) or Burning Mouth Syndrome (BMS) and to describe their treatment. Material and methods: a retrospective observational study was made, reviewing the clinical history of the patients diagnosed with Continuous Neuropathic Orofacial Pain between 2004 and 2011 at the Orofacial Pain Unit of the Master of Oral Surgery and Implantology of the University of Barcelona and at the Orofacial Pain Unit of the Teknon Medical Center of Barcelona. Results: the average age of the patients with Continuous Neuropathic Orofacial Pain was 54.5, with a clear female predominance (86.9%, n=20). Of all patients, 60.9% (n=14) were suffering a PIFP, 21.7% (n=5) had a BMS and 17.4% (n=4) were presenting a PPTTN. The pain quality described by the patients with Continuous Neuropathic Orofacial Pain was oppressive (43.47%, n=10), widely represented by patients with PIFP, and burning (39.13%, n=9) being the only quality that described patients with BMS. The treatment carried out with the patients was only pharmacologic. The most used drugs for the treatment of PIFP and PPTTN were clonazepam (50%, n=9) and amitriptyline (44.44%, n=8). However, a 55.5% (n=10) of the patients with PIFP or PPTTN required the association of two or more drugs for a correct pain control. All the patients with BMS responded satisfactorily to clonazepam. Conclusions: continuous Neuropathic Orofacial Pain is a little known condition among the general population, physicians and dentists. This favors a late diagnosis and inaccurate treatments which entail unnecessary suffering. It is important to inform both the general population and health professionals concerning this painful condition.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMedicina Oral SL-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.4317/jced.52560-
dc.relation.ispartofJournal of Clinical and Experimental Dentistry, 2016, vol. 8, num. 2, p. 153-159-
dc.relation.urihttps://doi.org/10.4317/jced.52560-
dc.rights(c) Medicina Oral SL, 2016-
dc.subject.classificationDolor facial-
dc.subject.classificationDolor orofacial-
dc.subject.classificationEstudi de casos-
dc.subject.otherFacial pain-
dc.subject.otherOrofacial pain-
dc.subject.otherCase studies-
dc.titleContinuous neurophatic orofacial pain: a retrospective study of 23 cases-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec661013-
dc.date.updated2020-05-05T11:10:17Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Odontoestomatologia)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
661013.pdf664.44 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.